.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,051,610

« Back to Dashboard

Details for Patent: 6,051,610

Title: Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Abstract:Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).
Inventor(s): Mueller; Alan L. (Salt Lake City, UT), Balandrin; Manuel F. (Sandy, UT), Van Wagenen; Bradford C. (Salt Lake City, UT), DelMar; Eric G. (Salt Lake City, UT), Moe; Scott T. (Salt Lake City, UT), Artman; Linda D. (Salt Lake City, UT), Barmore; Robert M. (Salt Lake City, UT)
Assignee: NPS Pharmaceuticals, Inc. (Salt Lake City, UT)
Filing Date:Feb 18, 1999
Application Number:09/252,433
Claims:1. A compound selected from the group consisting of ##STR116## and pharmaceutically acceptable salts and complexes thereof.

2. A compound having the chemical structure ##STR117## or a pharmaceutically acceptable salt or complex thereof.

3. A compound having the chemical structure ##STR118## or a pharmaceutically acceptable salt or complex thereof.

4. A pharmaceutical composition comprising a compound which is selected from the group consisting of ##STR119## and pharmaceutically acceptable salts and complexes thereof, in a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising a compound having the chemical structure ##STR120## or a pharmaceutically acceptable salt or complex thereof, in a pharmaceutically acceptable carrier.

6. A pharmaceutical composition comprising a compound having the chemical structure ##STR121## or a pharmaceutically acceptable salt or complex thereof, in a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 5 or 6, adapted for the treatment of a neurological disease or disorder.

8. The pharmaceutical composition of claim 7, wherein said neurological disease or disorder is selected from the group consisting of stroke, head trauma, spinal cord injury, epilepsy, anxiety, Alzheimer's disease, Huntington's disease, Parkinson's disease, or amyotrophic lateral sclerosis.

9. The pharmaceutical composition of claim 5 or 6, wherein said pharmaceutical composition has neuroprotectant activity.

10. The pharmaceutical composition of claim 8, wherein said stroke is global ischemic.

11. The pharmaceutical composition of claim 8, wherein said stroke is hemorrhagic.

12. The pharmaceutical composition of claim 8 wherein said stroke is focal ischemic.

13. The phannaceutical composition of claim 8 wherein said neurological disease or disorder is Parkinson's disease.

14. A method for treating a patient having a neurological disease or disorder, comprising administering a compound which is selected from the group consisting of ##STR122## and pharmaceutically acceptable salts and complexes thereof.

15. The method of claim 14, wherein said compound is ##STR123## or a pharmaceutically acceptable salt or complex thereof.

16. The method of claim 14, wherein said compound is ##STR124## or a pharmaceutically acceptable salt or complex thereof.

17. The method of claim 15 or 16, wherein the neurological disease or disorder comprises stroke, head trauma, spinal cord injury, epilepsy, anxiety, Alzheimer's disease, Huntington's disease, Parkinson's disease, or amyotrophic lateral sclerosis.

18. The method of claim 17 wherein said stroke is global ischemic.

19. The method of claim 17 wherein said stroke is hemorrhagic.

20. The method of claim 17 wherein said stroke is focal ischemic.

21. The method of claim 17 wherein the neurological disease or disorder comprises Parkinson's disease.

22. A method for providing neuroprotection to a patient, comprising administering a compound which is selected from the group consisting of ##STR125## and pharmaceutically acceptable salts and complexes thereof.

23. The method of claim 22 wherein said compound is ##STR126## or a pharmaceutically acceptable salt or complex thereof.

24. The method of claim 22 wherein said compound is ##STR127## or a pharmaceutically acceptable salt or complex thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc